The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-24. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
=== United Kingdom === In the United Kingdom, following a local newspaper story in October 2005, a parliamentary Early Day Motion was raised calling for Salvia divinorum to be banned there. However, it only received 11 signatures. A second motion raised in October 2008 attracted 18 signatures, and it was reported that Mann had also written to Jacqui Smith, then Home Secretary. The Advisory Council on the Misuse of Drugs, the independent body that advises UK government on drugs, was asked to investigate further. On the 28 January 2016, the Psychoactive Substances Act 2016 was passed. The act came into force on 26 May 2016, across the entire United Kingdom, making S. divinorum illegal to possess with intent to supply, possess on custodial premises, import for human consumption, or produce for human consumption. The two sponsors for the bill were Conservative House of Lords member Michael Bates and Conservative MP Theresa May.
=== Mechanism of action === Elbasvir targets the NS5A protein, which effectively prevents the transcription of the HCV RNA and also prevents virion assembly. "Median EC50 values range from 0.2 to 3600 pmol/L, based on genotype." Grazoprevir is an protease inhibitor targeting HCV NS3/4A serine protease. Effectively grazoprevir prevents cleavage of the necessary polyproteins for replication.
== Notes == An α indicates the medicine is on the complementary list for which specialized diagnostic or monitoring or training is needed. An item may also be listed as complementary on the basis of higher costs or a less attractive cost-benefit ratio.
Sources: en.wikipedia.org
=== Ehlers–Danlos syndrome hypermobility type === Joint hypermobility is often correlated with hypermobile Ehlers–Danlos syndrome (hEDS, known also by EDS type III or Ehlers–Danlos syndrome hypermobility type (EDS-HT)). Ehlers–Danlos syndrome is a genetic disorder caused by mutations or hereditary genes, but the genetic defect that produces hEDS is largely unknown. In conjunction with joint hypermobility, a common symptom for hEDS is smooth, velvety, and stretchy skin. When diagnosing hEDS, the Beighton Criteria are used, but are not always able to distinguish between joint hypermobility syndrome and hEDS. Ehlers–Danlos hypermobility type can have severe musculoskeletal effects, including:
Drug carriers: Carriers such as "Trojan horse" molecules, liposomes, and nanoparticles might theoretically allow a therapeutic drug to enter the brain. Such tactics are mostly in the investigatory stages and are not yet clinically relevant to brain tumour treatment.
However, the Smith government still professed loyalty to Elizabeth II, and accordingly the document reconstituted Rhodesia as a Commonwealth realm with Elizabeth as "Queen of Rhodesia". The new constitution created the concept of allegiance to the "Constitution of Rhodesia", and introduced the post of Officer Administering the Government, a viceregal figure empowered to sign passed legislation into law on behalf of the monarch if she did not appoint a Governor-General. The Rhodesian Cabinet waited in vain for Wilson's reply for the rest of 9 November and the next day. After briefly meeting Smith late on 10 November, Johnston warned Wilson that evening that the Rhodesians seemed poised to declare independence in the morning. The British prime minister tried repeatedly to call Smith, but did not get through until Smith was already chairing a Cabinet meeting on the independence issue around 08:00 Central Africa Time (06:00 in London) on 11 November. Wilson attempted to talk Smith out of unilateral action by telling him the status quo could continue, and the two argued inconclusively about the proposed Royal Commission. Returning to his Cabinet meeting, Smith reported the conversation to his ministers, and, after debating for a while, the Cabinet came to the conclusion that Wilson was simply attempting to buy more time and that there was no sign of actual progress. Smith asked if Rhodesia should declare its independence, and had each Cabinet minister answer in turn.
Sources: en.wikipedia.org
=== Human health === The effect of rBGH on human health is an ongoing debate, in part due to the lack of conclusive evidence. A few of the most debated issues include: Insulin-like growth factor 1 (IGF-1) is a hormone found in humans that is responsible for growth promotion, protein synthesis, and insulin actions over the lifecycle. The hormone has been shown to influence the growth of tumors in some studies and may be linked to the development of prostate, colorectal, breast, and other cancers. IGF-1 is also found in milk. Previous research has proposed an increase of IGF-1 in rBST-treated cows, but this claim is currently not substantiated. In addition, no current evidence shows that orally consumed IGF-1 is absorbed in humans and the dietary amount is negligible when compared to what the body produces on its own. "IGF-1 in milk is not denatured (inactivated) by pasteurization. The extent to which intact, active IGF-1 is absorbed through the human digestive tract remains uncertain." The American Cancer Society has reviewed the evidence concerning IGF-1 in milk from rBST-treated cows, and found that: "While there may be a link between IGF-1 blood levels and cancer, the exact nature of this link remains unclear. Some studies have shown that adults who drink milk have about 10% higher levels of IGF-1 in their blood than those who drink little or no milk. But this same finding has also been reported in people who drink soy milk.
=== La Basilique des Saints-Apôtres (Church of the Holy Apostles) === Alexandre Raymond became interested in Christian art and developed a technique that required great rigour, which we could call “micro-mosaics”. By drawing from the texts written by Procopius of Caesarea, Constantine of Rhodes and Constantine Mazarius, he drew 35 representations of the Church of the Holy Apostles including a series of illustrations of the life of Jesus.
Moreover, other undetermined proteins may be a part of Ppk1/Ppk26 channel complex, as co-expression of exclusively Ppk and Bba together does not produce mechanosensitive currents. Even very diluted concentrations of velvet ant venom (1:8,192) activate cIV da nociceptors through Ppk1/Ppk26, meaning that the key venom peptide is highly potent and affinitive.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.